Skip to main content

Table 2 Associations between mammography behaviour and disease characteristics

From: Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall survival: case-only analysis of 3739 Asian breast cancer patients

 

Screeners, n=1089

Non-screeners, n=2260

Unaware, n=390

N

 

N

OR (95% CI)

P

N

OR (95% CI)

P

Stage

 I

521

1.00 (reference)

694

  

90

  

 II

437

 

1011

1.72 (1.46–2.02)

<0.001

194

2.72 (2.02–3.65)

<0.001

 III

131

 

555

3.17 (2.52–3.98)

<0.001

106

4.94 (3.45–7.07)

<0.001

Grade

 Well-differentiated

190

1.00 (reference)

284

  

59

  

 Moderately differentiated

451

 

949

1.41 (1.13–1.76)

0.002

149

1.15 (0.80–1.65)

0.461

 Poorly differentiated

413

 

941

1.58 (1.26–1.97)

<0.001

160

1.53 (1.06–2.20)

0.022

 Missing

35

 

86

  

22

  

Nodal status

 Negative

739

1.00 (reference)

1269

  

208

  

 Positive

345

 

959

1.61 (1.38–1.89)

<0.001

180

1.96 (1.52–2.52)

<0.001

 Missing

5

 

32

  

2

  

Tumour size

 ≤2cm

643

1.00 (reference)

947

  

133

  

 >2–≤5cm

389

 

1037

1.73 (1.48–2.03)

<0.001

204

2.43 (1.86–3.16)

<0.001

 >5cm

40

 

205

3.22 (2.25–4.61)

<0.001

44

5.06 (3.10–8.25)

<0.001

 Missing

17

 

71

  

9

  

Oestrogen receptor status

 Positive

775

1.00 (reference)

1538

  

277

  

 Negative

231

 

514

1.12 (0.93–1.34)

0.225

85

1.10 (0.82–1.48)

0.516

 Missing

83

 

208

  

28

  

Progesterone receptor status

 Positive

642

1.00 (reference)

1316

  

247

  

 Negative

364

 

727

1.00 (0.85–1.17)

0.989

116

0.92 (0.70–1.20)

0.54

 Missing

83

 

217

  

27

  

HER2 status

 Positive

236

1.00 (reference)

540

  

89

  

 Negative

714

 

1415

0.80 (0.67–0.96)

0.016

252

0.72 (0.53–0.97)

0.028

 Missing

139

 

305

  

49

  

Subtype

 Luminal A

445

1.00 (reference)

880

  

156

  

 Luminal B [HER2-negative]

159

 

354

1.15 (0.92–1.44)

0.206

69

1.44 (1.01–2.05)

0.041

 Luminal B [HER2-positive]

8

 

22

1.48 (0.65–3.38)

0.352

6

2.53 (0.81–7.84)

0.109

 HER2-overexpressed

86

 

219

1.39 (1.05–1.83)

0.022

31

1.40 (0.88–2.23)

0.158

 Triple negative

107

 

204

0.96 (0.74–1.25)

0.754

39

1.12 (0.73–1.72)

0.607

 Missing

284

 

581

  

89

  
  1. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multinomial regression. P indicates the p-value obtained from the Wald test. The model was adjusted for age at diagnosis, site, ethnicity, and case type (incident/prevalent). Bold indicates statistical significance at p-value <.05